Zelluna Feed

2026-06-29 13:03:47 Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement

2026-06-29 09:59:20 Zelluna ASA: New share capital registered

2026-06-29 08:30:00 Zelluna ASA aktiverer The Royal Marsden som det andre kliniske senteret for ZIMA-101, og utvider kapasiteten for klinisk gjennomføring

2026-06-29 08:30:00 Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

2026-06-29 08:30:00 ZLNA: Zelluna ASA aktiverer The Royal Marsden som det andre kliniske senteret for ZIMA-101, og utvider kapasiteten for klinisk gjennomføring

2026-06-29 08:30:00 ZLNA: Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

2026-06-26 16:40:00 Resultater fra Ultimovacs' DOVACC fase II-studie bekrefter avslutningen av UV1-programmet, i tråd med tidligere kommunisert plan

2026-06-26 16:40:00 Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

2026-06-18 11:08:33 Zelluna ASA: Disclosure of large shareholding 18,70 NOK | -9,22% | 60,9 MNOK

2026-06-18 11:08:18 Zelluna ASA: Disclosure of large shareholding 18,70 NOK | -9,22% | 60,9 MNOK

2026-06-18 00:28:14 Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement 20,60 NOK | -2,37% | 0,32 MNOK

2026-06-18 00:21:37 Zelluna ASA: Private Placement and Retail Offering successfully placed 20,60 NOK | -2,37% | 0,32 MNOK

2026-06-17 16:47:04 Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data 18,70 NOK | -9,22% | 60,9 MNOK

2026-05-07 07:00:00 Zelluna ASA: Første kvartal 2026 22,60 NOK | +1,35% | 0,19 MNOK

2026-05-07 07:00:00 Zelluna ASA: First Quarter 2026 results 22,60 NOK | +1,35% | 0,19 MNOK

2026-05-06 23:18:55 Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution 22,60 NOK | +1,35% | 0,19 MNOK

2026-05-06 23:18:55 Zelluna ASA aktiverer det første kliniske senteret for ZIMA-101studien, og markerer dermed oppstart av klinisk gjennomføring 22,60 NOK | +1,35% | 0,19 MNOK

2026-05-04 17:58:23 Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time) 22,70 NOK | +2,71% | 0,51 MNOK

2026-05-04 15:19:15 Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation 22,10 NOK | -0,45% | 0,53 MNOK

2026-04-23 09:37:27 Zelluna ASA – Annual General Meeting held on April 23, 2026 23,10 NOK | +1,32% | 1,31 MNOK

2026-04-08 11:26:05 Zelluna ASA – Disclosure of voting rights of Annual General Meeting 19,10 NOK | 0,00% | 0,52 MNOK

2026-04-08 11:25:50 Zelluna ASA - Disclosure of voting rights of Annual General Meeting 19,10 NOK | 0,00% | 0,52 MNOK

2026-03-27 10:01:45 Zelluna ASA – Mandatory notification of trade 19,29 NOK | -0,70% | 1,09 MNOK

2026-03-26 15:28:52 Zelluna to host Capital Markets Update 2026 19,43 NOK | -2,45% | 1,25 MNOK

2026-03-26 15:28:37 ZLNA: Zelluna to host Capital Markets Update 2026 19,43 NOK | -2,45% | 1,25 MNOK

2026-03-26 08:57:12 Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 19,43 NOK | -2,45% | 1,25 MNOK

2026-03-25 07:00:00 Zelluna ASA [ZLNA]: Annual Report 2025 19,92 NOK | +1,11% | 0,69 MNOK

2026-03-09 08:00:01 ZLNA: Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling 16,13 NOK | +3,44% | 0,21 MNOK

2026-03-09 08:00:00 Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling 16,13 NOK | +3,44% | 0,21 MNOK

2026-03-09 08:00:00 Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering 16,13 NOK | +3,44% | 0,21 MNOK

2026-03-09 08:00:00 ZLNA: Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering 16,13 NOK | +3,44% | 0,21 MNOK

2026-02-20 14:30:00 Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie 18,00 NOK | +13,19% | 1,52 MNOK

2026-02-20 14:30:00 Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial 18,00 NOK | +13,19% | 1,52 MNOK

2026-02-12 07:00:00 Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd med CTA-innlevering 15,95 NOK | +2,94% | 0,45 MNOK

2026-02-12 07:00:00 Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission 15,95 NOK | +2,94% | 0,45 MNOK

2026-02-11 08:00:00 Zelluna inngår avtale med Medpace om første kliniske studie – pasientdata ventes fra medio 2026 15,50 NOK | +2,64% | 0,99 MNOK

2026-02-11 08:00:00 Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial 15,50 NOK | +2,64% | 0,99 MNOK

2026-02-11 08:00:00 Zelluna inngår avtale med Medpace om første kliniske studie - pasientdata ventes fra medio 2026 15,50 NOK | +2,64% | 0,99 MNOK

2026-02-11 08:00:00 ZLNA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial 15,50 NOK | +2,64% | 0,99 MNOK

2026-02-05 13:30:31 Zelluna ASA - Grant of Share Options 15,20 NOK | +6,31% | 0,63 MNOK

2026-02-05 09:30:00 Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation 15,20 NOK | +6,31% | 0,63 MNOK

2026-02-03 08:00:01 ZLNA: Zelluna utnevner Emilie Gauthy til Chief Technology Officer 14,11 NOK | -0,66% | 0,15 MNOK

2026-02-03 08:00:01 ZLNA: Zelluna promotes Emilie Gauthy to Chief Technology Officer 14,11 NOK | -0,66% | 0,15 MNOK

2026-02-03 08:00:00 Zelluna promotes Emilie Gauthy to Chief Technology Officer 14,11 NOK | -0,66% | 0,15 MNOK

2026-02-03 08:00:00 Zelluna utnevner Emilie Gauthy til Chief Technology Officer 14,11 NOK | -0,66% | 0,15 MNOK

2026-01-15 12:23:12 Zelluna ASA: Approval and publication of prospectus 13,70 NOK | 0,00% | 0,21 MNOK

2025-12-17 17:26:21 Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer. 15,30 NOK | +28,59% | 5,61 MNOK

2025-12-17 17:26:21 Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours 15,30 NOK | +28,59% | 5,61 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode